scispace - formally typeset
A

Angelo A. Manfredi

Researcher at Vita-Salute San Raffaele University

Publications -  286
Citations -  24292

Angelo A. Manfredi is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Inflammation & Immune system. The author has an hindex of 66, co-authored 272 publications receiving 20833 citations. Previous affiliations of Angelo A. Manfredi include Mario Negri Institute for Pharmacological Research & University of Milan.

Papers
More filters
Journal ArticleDOI

Are atopy and eosinophilic bronchial inflammation associated with relapsing forms of chronic rhinosinusitis with nasal polyps

TL;DR: Atopy, severe asthma, bronchial inflammation, NSAIDs hypersensitivity and high level of total IgE are possible useful prognostic factors for the proneness to relapse after FESS and the role of allergy in CRSwNP pathogenesis should be given deeper consideration.
Journal ArticleDOI

High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment.

TL;DR: Giant cell arteritis rapidly responds to high-dose corticosteroids, however, smouldering arterial inflammation can persist despite the absence of symptoms and altered acute phase reactants, and Chromogranin A in particular is a candidate marker linking neurogenic inflammation and vascular inflammation.
Journal ArticleDOI

T cells in myasthenia gravis specific for embryonic acetylcholine receptor.

TL;DR: In this paper, propagation from the blood of MG patients of T helper (T H ) cell lines specific for human embryonic AChR, by cycles of stimulation with a pool of synthetic peptides corresponding to the complete sequence of the γ subunit (γ pool), was reported.
Journal ArticleDOI

Chromogranin-A production and fragmentation in patients with Takayasu arteritis

TL;DR: The plasma levels of CgA fragments are markedly increased in TA as a consequence of disease- and therapy-related variables and it is advisable to limit the therapeutic prescriptions that might influence C gA-derived peptide levels to clearly agreed medical indications until further data become available.